Ann: Positive IHL-675A in vivo results and FDA Pathway, page-9

This is an excellent ann, no wonder the ASX scrutinized it so heavily.

I am really glad Camargo will accompany us when meeting with the FDA, their expertise is invaluable.

My previous example to Tetra Biopharma and their ARDS-003 drug I think gives confidence to IHL's meeting with the FDA as ARDS-003 was granted a Pre-IND and ability to conduct Phase 1 human trials in COVID-19 patients. And their drug is just synthetic CBD, IHL-675A continues to outperform CBD immensely as can be seen by these In Vivo results.

Future looks bright!